Bibliography
- World Alzheimer Report 2013. Journey of Caring. An analysis of long-term care for dementia. Alzheimer’s Disease International; London, UK; 2013
- Friedrich MJ. Researchers test strategies to prevent Alzheimer’s disease. JAMA 2014;311:1596-8
- Toyohara J, Hashimoto K. Alpha7 Nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer’s disease. Open Med Chem J 2010;4:37-46
- Deutsch SI, Burket JA, Benson AD. Targeting the alpha7 nicotinic acetylcholine receptor to prevent progressive dementia and improve cognition in adults with Down’s syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2014;54:131-9
- Dziewczapolski G, Glogowski CM, Masliah E, et al. Deletion of the alpha7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer’s disease. J Neurosci 2009;29:8805-15
- Srivareerat M, Tran TT, Salim S, et al. Chronic nicotine restores normal Abeta levels and prevents short-term memory and E-LTP impairment in Abeta rat model of Alzheimer’s disease. Neurobiol Aging 2011;32:834-44
- Wang HY, Bakshi K, Shen C, et al. S 24795 limits beta-amyloid - alpha7 nicotinic receptor interaction and reduces Alzheimer’s disease-like pathologies. Biol Psychiatry 2010;67:522-30
- Koike K, Hashimoto K, Takai N, et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 2005;76:67-72
- Shiina A, Shirayama Y, Niitsu T, et al. A randomized, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry 2010;9:27
- Zhang XY, Liu L, Liu S, et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry 2012;169:974-81
- Noroozian M, Ghasemi S, Hosseini SM, et al. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology (Berl) 2013;228:595-602
- Ishikawa M, Hashimoto K. Alpha7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia. Curr Pharm Des 2011;17:121-9
- Spilman P, Descampus O, Gorostiza O, et al. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer’s model. Brain Res 2014;1551:25-44
- Rahimian R, Fakhfouri G, Ejtemaei Mehr S, et al. Tropisetron attenuates amyloid-beta -induced inflammatory and apoptotic responses in rats. Eur J Clin Invest 2014;43:1039-51
- Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009;72:56-62
- Cohen AD, Klunk WE. Early detection of Alzheimer’s disease using PIB and FDG PET. Neurobiol Dis 2014;72:117-122
- Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384-8
- Matteoli G, Boeckxstaens GE. The vagal innervation of the gut and immune homeostasis. Gut 2013;62:1214-22
- Setoguchi D, Nakamura M, Yatsuki H, et al. Experimental examination of anti-inflammatory effects of a 5-HT3 receptor antagonist, tropisetron, and concomitant effects on autonomic nervous function in a rat sepsis model. Int Immunopharmacol 2011;11:2073-8
- Forum Pharmaceuticals, Inc. EnEivo Pharmaceuticals initiates COGNITIV AD, a phase 3 clinical trial program of encenicline (EVP-6124) in Alzheimer’s disease. January 22 2014. Available from: http://www.forumpharma.com/content/news-events/cognitiv-ad-program